Cargando…

Cell-free DNA 5-hydroxymethylcytosine is highly sensitive for MRD assessment in acute myeloid leukemia

Measurable residual disease (MRD) is an important biomarker in acute myeloid leukemia (AML). However, MRD cannot be detected in many patients using current methods. We developed a highly sensitive 5-hydroxymethylcytosine (5hmC) signature in cell-free DNA by analyzing 115 AML patients and 86 controls...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shao, Jianming, Shah, Shilpan, Ganguly, Siddhartha, Zu, Youli, He, Chuan, Li, Zejuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10464230/ https://www.ncbi.nlm.nih.gov/pubmed/37620919 http://dx.doi.org/10.1186/s13148-023-01547-0

Ejemplares similares

Classification of Acute Myeloid Leukemia by Cell-Free DNA 5-Hydroxymethylcytosine
por: Shao, Jianming, et al.
Publicado: (2023)

Cell-free DNA 5-hydroxymethylcytosine is an emerging marker of acute myeloid leukemia
por: Shao, Jianming, et al.
Publicado: (2022)

Urine cell-free DNA multi-omics to detect MRD and predict survival in bladder cancer patients
por: Chauhan, Pradeep S., et al.
Publicado: (2023)

Editorial: Acute myeloid leukemia (AML): Is it time for MRD-driven treatment?
por: Guolo, Fabio, et al.
Publicado: (2022)

Notch signaling genes: Myogenic DNA hypomethylation and 5-hydroxymethylcytosine
por: Terragni, Jolyon, et al.
Publicado: (2014)

Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances
por: Cumbo, Cosimo, et al.
Publicado: (2020)

Sensitive enzymatic quantification of 5-hydroxymethylcytosine in genomic DNA
por: Szwagierczak, Aleksandra, et al.
Publicado: (2010)

Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia
por: Shah, Shilpan, et al.
Publicado: (2014)

Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication
por: Tiong, Ing S., et al.
Publicado: (2023)

Steadfast Toll Like Receptor 4 (TLR4) 5-Hydroxymethylcytosine Levels in Cell-Free DNA: A Promising Consistency Marker for Colorectal Cancer Patients
por: Jevšinek Skok, Daša, et al.
Publicado: (2023)

SERS-Based Assessment of MRD in Acute Promyelocytic Leukemia?
por: Turcas, Cristina, et al.
Publicado: (2020)

5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic biomarkers for human cancers
por: Li, Wenshuai, et al.
Publicado: (2017)

Effect of Measurable (“Minimal”) Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia
por: Othus, Megan, et al.
Publicado: (2016)

DNA damage in acute myeloid leukemia patients of Northern Mexico
por: Dávila-Rodríguez, Martha I., et al.
Publicado: (2017)

Placental 5-methylcytosine and 5-hydroxymethylcytosine patterns associate with size at birth
por: Piyasena, Chinthika, et al.
Publicado: (2015)

P497: CLINICAL OUTCOMES OF NPM1-MUTATED ACUTE MYELOID LEUKEMIA (AML) PATIENTS WITH MEASURABLE RESIDUAL DISEASE (MRD) RELAPSE AFTER ACHIEVEMENT OF A FIRST MRD-NEGATIVE REMISSION
por: Jentzsch, Madlen, et al.
Publicado: (2023)

NGS-defined measurable residual disease (MRD) after initial chemotherapy as a prognostic biomarker for acute myeloid leukemia
por: Li, Yonghong, et al.
Publicado: (2023)

5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic and predictive biomarkers for coronary artery disease
por: Dong, Chaoran, et al.
Publicado: (2020)

Base resolution maps reveal the importance of 5-hydroxymethylcytosine in a human glioblastoma
por: Raiber, Eun-Ang, et al.
Publicado: (2017)

5‐Hydroxymethylcytosine profiling from genomic and cell‐free DNA for colorectal cancers patients
por: Gao, Pingting, et al.
Publicado: (2019)

5-Hydroxymethylcytosines in circulating cell-free DNA reveal a diagnostic biomarker for glioma
por: Zhang, Chunyu, et al.
Publicado: (2022)

PB1814: RARE PHENOTYPE WITH CD33 ABSENT IN ACUTE MYELOID LEUKEMIA MIMICKING MRD POSITIVITY: A CASE REPORT
por: O Marani, L., et al.
Publicado: (2022)

Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party
por: Tettero, Jesse M., et al.
Publicado: (2021)

5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA as Early Warning Biomarkers for COVID-19 Progression and Myocardial Injury
por: Chen, Hang-yu, et al.
Publicado: (2022)

5-Hydroxymethylcytosine signatures in cell-free DNA provide information about tumor types and stages
por: Song, Chun-Xiao, et al.
Publicado: (2017)

Quantifying mammalian genomic DNA hydroxymethylcytosine content using solid-state nanopores
por: Zahid, Osama K., et al.
Publicado: (2016)

Clofarabine Improves Relapse-Free Survival of Acute Myeloid Leukemia in Younger Adults with Micro-Complex Karyotype
por: Fenwarth, Laurène, et al.
Publicado: (2019)

Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia
por: Kayser, S, et al.
Publicado: (2016)

MRD abnormal expression predict poor outcomes for refractory or relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
por: Hao, Qi, et al.
Publicado: (2021)

Characterization of the 5-hydroxymethylcytosine-specific DNA restriction endonucleases
por: Borgaro, Janine G., et al.
Publicado: (2013)

5-Hydroxymethylcytosine Is Not Present in Appreciable Quantities in Arabidopsis DNA
por: Erdmann, Robert M., et al.
Publicado: (2014)

An integrative analysis of genome-wide 5-hydroxymethylcytosines in circulating cell-free DNA detects noninvasive diagnostic markers for gliomas
por: Cai, Jiajun, et al.
Publicado: (2021)

Bisulfite-free, single base-resolution analysis of 5-hydroxymethylcytosine in genomic DNA by chemical-mediated mismatch
por: Wang, Yafen, et al.
Publicado: (2018)

Detection of early stage pancreatic cancer using 5-hydroxymethylcytosine signatures in circulating cell free DNA
por: Guler, Gulfem D., et al.
Publicado: (2020)

5-Hydroxymethylcytosine profiles in plasma cell-free DNA reflect molecular characteristics of diabetic kidney disease
por: Chu, Jin-Lin, et al.
Publicado: (2022)

Genome-wide profiling of 5-hydroxymethylcytosines in circulating cell-free DNA reveals population-specific pathways in the development of multiple myeloma
por: Chiu, Brian C.-H., et al.
Publicado: (2022)

Correction Notice: Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party
Publicado: (2022)

5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia
por: Ahn, Jae-Sook, et al.
Publicado: (2016)

411 Mrd. €, 11,9 %
por: Kuhn, Joseph
Publicado: (2022)

Changes of 5-hydroxymethylcytosine distribution during myeloid and lymphoid differentiation of CD34+ cells
por: Tekpli, Xavier, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_82evruoau3lovhg5i5s1hviu3o